{"id":36066,"date":"2025-06-26T15:33:44","date_gmt":"2025-06-26T07:33:44","guid":{"rendered":"https:\/\/flcube.com\/?p=36066"},"modified":"2025-06-26T15:33:44","modified_gmt":"2025-06-26T07:33:44","slug":"eli-lillys-amyvid-sees-fda-approved-label-update-for-alzheimers-diagnosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36066","title":{"rendered":"Eli Lilly’s Amyvid Sees FDA-Approved Label Update for Alzheimer’s Diagnosis"},"content":{"rendered":"\n

US-based Eli Lilly & Co. (NYSE: LLY<\/a>) announced the US Food and Drug Administration (FDA) has approved a label update for Amyvid (florbetapir F18 injection). The revised label broadens the use of this radioactive diagnostic agent for brain imaging in assessing amyloid plaque density in Alzheimer’s disease (AD) and other cognitive impairments.<\/p>\n\n\n\n

Label Updates<\/strong>
The updated label provides revised guidance on using Amyvid to evaluate plaque density in AD patients and those with cognitive decline who may be candidates for amyloid-targeting therapies. It introduces new indications for patient selection in amyloid-targeted therapy and clarifies that quantification of amyloid plaque levels may be used alongside visual interpretation.<\/p>\n\n\n\n

Clinical Studies Section<\/strong>
The label now includes an updated clinical studies section noting that amyloid beta PET imaging has been used to assess plaque reduction in clinical trials of anti-amyloid therapies, as described in respective prescribing information.<\/p>\n\n\n\n

Amyvid Mechanism<\/strong>
Amyvid, labeled with fluorine-18, binds to amyloid plaques in the brain. When injected intravenously, it generates images via PET scanning. Qualified radiologists interpret these images to detect moderate to frequent neuritic plaque presence, aiding clinicians in diagnostic and treatment decisions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Eli Lilly & Co. (NYSE: LLY) announced the US Food and Drug Administration (FDA)…<\/p>\n","protected":false},"author":1,"featured_media":36068,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[199,911,15],"class_list":["post-36066","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-eli-lilly","tag-nyse-lly","tag-product-approvals"],"yoast_head":"\nEli Lilly's Amyvid Sees FDA-Approved Label Update for Alzheimer's Diagnosis - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Eli Lilly & Co. (NYSE: LLY) announced the US Food and Drug Administration (FDA) has approved a label update for Amyvid (florbetapir F18 injection). The revised label broadens the use of this radioactive diagnostic agent for brain imaging in assessing amyloid plaque density in Alzheimer's disease (AD) and other cognitive impairments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36066\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly's Amyvid Sees FDA-Approved Label Update for Alzheimer's Diagnosis\" \/>\n<meta property=\"og:description\" content=\"US-based Eli Lilly & Co. (NYSE: LLY) announced the US Food and Drug Administration (FDA) has approved a label update for Amyvid (florbetapir F18 injection). The revised label broadens the use of this radioactive diagnostic agent for brain imaging in assessing amyloid plaque density in Alzheimer's disease (AD) and other cognitive impairments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36066\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-26T07:33:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2606.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36066#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36066\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly’s Amyvid Sees FDA-Approved Label Update for Alzheimer’s Diagnosis\",\"datePublished\":\"2025-06-26T07:33:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36066\"},\"wordCount\":202,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36066#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2606.webp\",\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36066#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36066\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36066\",\"name\":\"Eli Lilly's Amyvid Sees FDA-Approved Label Update for Alzheimer's Diagnosis - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36066#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36066#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2606.webp\",\"datePublished\":\"2025-06-26T07:33:44+00:00\",\"description\":\"US-based Eli Lilly & Co. (NYSE: LLY) announced the US Food and Drug Administration (FDA) has approved a label update for Amyvid (florbetapir F18 injection). The revised label broadens the use of this radioactive diagnostic agent for brain imaging in assessing amyloid plaque density in Alzheimer's disease (AD) and other cognitive impairments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36066#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36066\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36066#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2606.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2606.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly's Amyvid Sees FDA-Approved Label Update for Alzheimer's Diagnosis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36066#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly’s Amyvid Sees FDA-Approved Label Update for Alzheimer’s Diagnosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's Amyvid Sees FDA-Approved Label Update for Alzheimer's Diagnosis - Insight, China's Pharmaceutical Industry","description":"US-based Eli Lilly & Co. (NYSE: LLY) announced the US Food and Drug Administration (FDA) has approved a label update for Amyvid (florbetapir F18 injection). The revised label broadens the use of this radioactive diagnostic agent for brain imaging in assessing amyloid plaque density in Alzheimer's disease (AD) and other cognitive impairments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36066","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's Amyvid Sees FDA-Approved Label Update for Alzheimer's Diagnosis","og_description":"US-based Eli Lilly & Co. (NYSE: LLY) announced the US Food and Drug Administration (FDA) has approved a label update for Amyvid (florbetapir F18 injection). The revised label broadens the use of this radioactive diagnostic agent for brain imaging in assessing amyloid plaque density in Alzheimer's disease (AD) and other cognitive impairments.","og_url":"https:\/\/flcube.com\/?p=36066","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-26T07:33:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2606.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36066#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36066"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly’s Amyvid Sees FDA-Approved Label Update for Alzheimer’s Diagnosis","datePublished":"2025-06-26T07:33:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36066"},"wordCount":202,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36066#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2606.webp","keywords":["Eli Lilly","NYSE: LLY","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36066#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36066","url":"https:\/\/flcube.com\/?p=36066","name":"Eli Lilly's Amyvid Sees FDA-Approved Label Update for Alzheimer's Diagnosis - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36066#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36066#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2606.webp","datePublished":"2025-06-26T07:33:44+00:00","description":"US-based Eli Lilly & Co. (NYSE: LLY) announced the US Food and Drug Administration (FDA) has approved a label update for Amyvid (florbetapir F18 injection). The revised label broadens the use of this radioactive diagnostic agent for brain imaging in assessing amyloid plaque density in Alzheimer's disease (AD) and other cognitive impairments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36066#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36066"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36066#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2606.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2606.webp","width":1080,"height":608,"caption":"Eli Lilly's Amyvid Sees FDA-Approved Label Update for Alzheimer's Diagnosis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36066#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly’s Amyvid Sees FDA-Approved Label Update for Alzheimer’s Diagnosis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2606.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36066"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36066\/revisions"}],"predecessor-version":[{"id":36069,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36066\/revisions\/36069"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36068"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}